Rheumatoid Arthritis (RA) is a chronic, systemic inflammatory autoimmune disease that affects up to 1% of the adult population across the developing world, including more than 1 million people in the US alone. As a result, RA represents the world’s biggest market for drug treatments, aside from oncology. Currently this market is dominated by two categories of treatment: non-steroidal anti-inflammatory drugs (NSAIDs), and biologic disease-modifying anti-rheumatic drugs (DMARDs). The gold standard of treatment has been an older oral DMARD methotrexate (MTX) which is included in most combination therapies but it is beset by unwelcome side-effects. Now the leading DMARDs target tumour necrosis factor (TNF), a key inflammatory mediator. These have had a major impact on outcomes, due to improved tolerability and efficacy
Lynette Linkson, Specialist Registrars in Respiratory Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK
Richard Leach, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
A 48-year-old man was referred to the chest clinic with uncontrolled adult-onset asthma and severe persistent cough despite repeated courses of oral steroids. Previously his asthma had been well controlled with a combined inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA).
Stephanie J. Dancer BSc, MB BS, MSc, MD, FRCPath, DTM&H, Consultant Microbiologist, NHS Lanarkshire, Scotland
A 72-year-old man was referred by his general practitioner complaining of intermittent pain in the legs on exercise.
Disappointing results mean MLN 8237 (alisertib) discontinued in T-Cell Lymphoma-Takeda
Oncology Drug News 8 days ago
Takeda Pharmaceuticals has announced that it has decided to discontinue the Phase III trial of MLN 8237 (alisertib) for patients...
GSK 2696273 is filed at EMA to treat adenosine deaminase severe combined immunodeficiency syndrome (ADA-SCID)- GSK
Medical Genetics Drug News 07/05/15
GSK, Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) announced the submission of a marketing application to the European Medicines...
New data for Envarsus XR (tacrolimus extended release) in African-American Transplant patients- Veloxis Pharma
Transplantation Drug News 05/05/15
Veloxis Pharmaceuticals has announced that once-daily Envarsus XR (tacrolimus extended-release), for the prevention of organ rejection in adult kidney transplant...
FDA approves Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]) for Asthma in adults-Glaxo Smith Kline
Respiratory Drug News 02/05/15
The FDA has approved Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]), from Glaxo Smith Kline, for the once-daily treatment of asthma in...
Zinbryta (daclizumab) filed with FDA for Multiple Sclerosis-Biogen/AbbVie
Neurological Disorders Drug News 30/04/15
The FDA has accepted for review the companies’ Biologics License Application (BLA) requesting marketing approval of Zinbryta (daclizumab high-yield process),...
Titles are scarce in this republican heartland, and those few we do recognise are quite diverse. Instead of Lords and Ladies, we have Doctors and Tits...
Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?Tue 14 Apr 2015 - Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?
BACKGROUND: Chemotherapy-induced febrile neutropenia (FN) with solid tumors causes mortality and morbidity at a significant rate. The purpose of this study was to compare the effects of filgastrim ...
Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high ...
Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary careFeb 2015
Key aspects of this guideline include establishing a diagnosis; referral into secondary care only..
The purpose of this guideline is to provide guidance on the management of patients with AL..
After completing this module, you should be able to: know what biological treatments are, be able to explain to patients how they work, know what conditions they are used for,...
After completing this module you should be able to: make a clinical diagnosis of myasthenia gravis, select appropriate diagnostic tests to confirm your diagnosis, and understand the principles of therapy...
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaWed 17 Dec 2014
The study is designed: - to demonstrate efficacy of AFM13 with an optimized treatment schedule - to decide whether AFM13 warrants further investigation in a phase III clinical ...
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (FLUGAZA)Wed 10 Dec 2014
The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm. To fulfill ...